Related references
Note: Only part of the references are listed.Myeloma today: Disease definitions and treatment advances
S. Vincent Rajkumar
AMERICAN JOURNAL OF HEMATOLOGY (2016)
Phase 3 trial of three thalidomide-containing regimens in patients with newly diagnosed multiple myeloma not transplant-eligible
V. T. M. Hungria et al.
ANNALS OF HEMATOLOGY (2016)
Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment
Paul G. Richardson et al.
BLOOD (2016)
Real-world treatment patterns, comorbidities, and disease-related complications in patients with multiple myeloma in the United States
Xue Song et al.
CURRENT MEDICAL RESEARCH AND OPINION (2016)
Better Therapy Requires Better Response Evaluation: Paving the Way for Minimal Residual Disease Testing for Every Myeloma Patient
Ola Landgren et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2016)
Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimen
Ruth M. de Tute et al.
HAEMATOLOGICA (2016)
Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimen
Ruth M. de Tute et al.
HAEMATOLOGICA (2016)
VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial
Philippe Moreau et al.
BLOOD (2016)
Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma
Herve Avet-Loiseau et al.
BLOOD (2016)
MRD-driven treatment paradigm for newly diagnosed transplant eligible multiple myeloma patients
O. Landgren et al.
BONE MARROW TRANSPLANTATION (2016)
Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis
O. Landgren et al.
BONE MARROW TRANSPLANTATION (2016)
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study
Meletios A. Dimopoulos et al.
LANCET ONCOLOGY (2016)
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
Shaji Kumar et al.
LANCET ONCOLOGY (2016)
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
P. Moreau et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
M. A. Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Antonio Palumbo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Phase 1/2 study of carfilzomib plus melphalan and prednisone in patients aged over 65 years with newly diagnosed multiple myeloma
Philippe Moreau et al.
BLOOD (2015)
Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma
A. Keith Stewart et al.
BLOOD (2015)
New criteria for response assessment: role of minimal residual disease in multiple myeloma
Bruno Paiva et al.
BLOOD (2015)
Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma
David H. Vesole et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Phase Ib/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myeloma
Joseph R. Mikhael et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Early Mortality in Elderly Patients With Newly Diagnosed Multiple Myeloma Treated With Novel Agents
A. Larocca et al.
Clinical Lymphoma Myeloma & Leukemia (2015)
An open-label phase I/II study of cyclophosphamide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed myeloma
Taiga Nishihori et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2015)
Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma
Jesus F. San Miguel et al.
HAEMATOLOGICA (2015)
Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens
Ruben Niesvizky et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma
E. K. Mai et al.
LEUKEMIA (2015)
Minimal residual disease in multiple myeloma: bringing the bench to the bedside
Sham Mailankody et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2015)
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
Sagar Lonial et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
A. Keith Stewart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma
Jesus F. San Miguel et al.
HAEMATOLOGICA (2015)
Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma
Neha Korde et al.
JAMA ONCOLOGY (2015)
Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma
Pieter Sonneveld et al.
BLOOD (2015)
The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma
Bruno Paiva et al.
HAEMATOLOGICA (2015)
Flow cytometry detection of minimal residual disease in multiple myeloma: Lessons learned at FDA-NCI roundtable symposium
Ola Landgren et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study
Sara Bringhen et al.
BLOOD (2014)
GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators?
Maria-Victoria Mateos et al.
BLOOD (2014)
Curing myeloma at last: defining criteria and providing the evidence
Bart Barlogie et al.
BLOOD (2014)
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial
Jesus F. San-Miguel et al.
LANCET ONCOLOGY (2014)
Association of response endpoints with survival outcomes in multiple myeloma
S. Lonial et al.
LEUKEMIA (2014)
IMWG consensus on risk stratification in multiple myeloma
W. J. Chng et al.
LEUKEMIA (2014)
Improved long-term survival in multiple myeloma up to the age of 80 years
S. Y. Kristinsson et al.
LEUKEMIA (2014)
Biological and Clinical Implications of Clonal Heterogeneity and Clonal Evolution in Multiple Myeloma
Giada Bianchi et al.
CURRENT CANCER THERAPY REVIEWS (2014)
Pursuing the curative blueprint for early myeloma
Mark Roschewski et al.
BLOOD (2013)
Assessment of molecular remission rate after bortezomib plus dexamethasone induction treatment and autologous stem cell transplantation in newly diagnosed multiple myeloma patients
Raija Silvennoinen et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Randomized Phase II Study of Bortezomib, Thalidomide, and Dexamethasone With or Without Cyclophosphamide As Induction Therapy in Previously Untreated Multiple Myeloma
Heinz Ludwig et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study
Meletios Dimopoulos et al.
LANCET ONCOLOGY (2013)
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
Jesus San Miguel et al.
LANCET ONCOLOGY (2013)
Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma
Shaji Kumar et al.
BLOOD (2012)
Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study
Laura Rosinol et al.
BLOOD (2012)
A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma
Andrzej J. Jakubowiak et al.
BLOOD (2012)
Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results
Gareth J. Morgan et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Superiority of the Triple Combination of Bortezomib-Thalidomide-Dexamethasone Over the Dual Combination of Thalidomide-Dexamethasone in Patients With Multiple Myeloma Progressing or Relapsing After Autologous Transplantation: The MMVAR/IFM 2005-04 Randomized Phase III Trial From the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation
Laurent Garderet et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/GMMG-HD4 Trial
Pieter Sonneveld et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
Michel Attal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
Philip L. McCarthy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma
Philippe Moreau et al.
BLOOD (2011)
The Progression from MGUS to Smoldering Myeloma and Eventually to Multiple Myeloma Involves a Clonal Expansion of Genetically Abnormal Plasma Cells
Lucia Lopez-Corral et al.
CLINICAL CANCER RESEARCH (2011)
Treatment Options for Relapsed and Refractory Multiple Myeloma
Sagar Lonial et al.
CLINICAL CANCER RESEARCH (2011)
MEDICAL PROGRESS Multiple Myeloma
Antonio Palumbo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma
Henk M. Lokhorst et al.
BLOOD (2010)
Bortezomib Plus Dexamethasone Is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone As Induction Treatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III Trial
Jean-Luc Harousseau et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study
Michele Cavo et al.
LANCET (2010)
Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial
Maria-Victoria Mateos et al.
LANCET ONCOLOGY (2010)
Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation
Bruno Paiva et al.
BLOOD (2008)